ORMP CEO reports tax withholding share disposition

ORAMED PHARMACEUTICALS INC.

Accepted by SEC EDGAR 03/31/2026 - 04:10 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

ORAMED PHARMACEUTICALS INC. President and CEO Nadav Kidron reported a routine tax-related share disposition. On March 30, 2026, 44,818 shares of common stock were used to satisfy tax withholding obligations from the vesting of Restricted Stock Units at $3.31 per share. These shares were not sold in the open market but withheld to cover taxes. Following this, Kidron directly holds 3,422,243 common shares and indirectly holds 126,000 common shares through a wholly-owned corporation.

Insider Trade Summary

Exercise Price or Tax Liability: 44,818 shares

Exercise Price or Tax Liability 1 txn

Insider KIDRON NADAV

Role President and CEO

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	44,818	$3.31	$148K
Holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 3,422,243 shares (Direct); Common Stock — 126,000 shares (Indirect, By wholly-owned corporation)

Holdings Before and After: Common Stock, 3,467,061 to 3,422,243 shares (Direct)

Footnotes (1)

1. F1. Represents shares of common stock, par value $0.012 per share ("Common Stock"), of the Issuer used to satisfy tax withholding obligations attributable to the vesting and settlement of Restricted Stock Units, which were valued at the closing price of the Issuer's Common Stock on the date immediately prior to the vesting date, equal to $3.31 per share.

Key Figures

Tax-withholding shares: 44,818 shares RSU tax valuation price: $3.31 per share Direct holdings after transaction: 3,422,243 shares +1 more

4 metrics

Tax-withholding shares 44,818 shares Common stock used to satisfy RSU tax obligations

RSU tax valuation price $3.31 per share Closing price on day before vesting used for tax withholding

Direct holdings after transaction 3,422,243 shares Common stock directly held by Nadav Kidron after withholding

Indirect holdings after transaction 126,000 shares Common stock held indirectly through a wholly-owned corporation

Key Terms

Restricted Stock Units, tax withholding obligations, wholly-owned corporation, common stock

4 terms

Restricted Stock Units financial

"vesting and settlement of Restricted Stock Units, which were valued at the closing price"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"used to satisfy tax withholding obligations attributable to the vesting and settlement"

wholly-owned corporation financial

"total_shares_following_transaction 126000.0000 ... nature_of_ownership By wholly-owned corporation"

common stock financial

"Represents shares of common stock, par value $0.012 per share ("Common Stock")"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ORMP CEO Nadav Kidron report on this Form 4?

Nadav Kidron reported that 44,818 ORMP common shares were used to cover tax withholding from vested Restricted Stock Units at $3.31 per share. This was a tax-withholding disposition rather than an open-market sale, tied directly to equity compensation vesting.

Were ORMP shares sold on the open market in this Form 4 filing?

No open-market sale occurred in this filing. The 44,818 ORMP shares were withheld by the issuer to satisfy Kidron’s tax obligations from RSU vesting, valued at the prior-day closing price of $3.31 per share, instead of being sold through the market.

How many ORMP shares does Nadav Kidron hold after the reported transactions?

After the tax-withholding disposition, Nadav Kidron directly holds 3,422,243 ORMP common shares. He also indirectly holds 126,000 additional common shares through a wholly-owned corporation, giving him substantial ongoing exposure to the company’s equity following this routine compensation-related event.

What price was used to value ORMP shares for the RSU tax withholding?

The RSU-related tax withholding used a valuation of $3.31 per ORMP share. This price reflects the closing price of Oramed Pharmaceuticals’ common stock on the trading day immediately before the vesting date, as specified in the Form 4 explanatory footnote.

Is the ORMP CEO’s Form 4 transaction a typical compensation-related event?

Yes, the Form 4 reflects a typical compensation-related event. Shares were withheld to cover tax obligations from Restricted Stock Units vesting, rather than indicating a discretionary buy or sell decision. Such tax-withholding dispositions are common for equity awards granted to senior executives.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KIDRON NADAV

(Last) (First) (Middle)

1185 AVENUE OF THE AMERICAS

THIRD FLOOR

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ORAMED PHARMACEUTICALS INC. [ ORMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/30/2026		F		44,818(1)	D	$3.31(1)	3,422,243	D
Common Stock								126,000	I	By wholly-owned corporation

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock, par value $0.012 per share ("Common Stock"), of the Issuer used to satisfy tax withholding obligations attributable to the vesting and settlement of Restricted Stock Units, which were valued at the closing price of the Issuer's Common Stock on the date immediately prior to the vesting date, equal to $3.31 per share.

	/s/ Nadav Kidron	03/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)